TABRECTA CAPMATINIB 卡马替尼

Capmatinib is an oral MET inhibitor primarily used to treat advanced or metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. It selectively inhibits MET tyrosine kinase activity, blocking related signaling pathways and thereby inhibiting tumor growth and spread. This drug should be used under a physician’s supervision. Common side effects include edema, nausea, and fatigue. Severe side effects require prompt medical attention and adjustment of treatment regimen.

Mechanism of Action and Indications

Mechanism of Action: Capmatinib inhibits MET protein (a receptor tyrosine kinase involved in tumor proliferation and metastasis), interfering with downstream signaling and inhibiting tumor cell growth.

Indications: It is indicated for patients with locally advanced or metastatic NSCLC who have been tested for MET exon 14 skipping mutations, typically as a second- or later-line treatment option.

Precautions

Genetic Testing: MET mutation status must be confirmed through tissue or blood testing before treatment to ensure targeted treatment. Dosage and Administration: The standard dose is taken orally twice daily. Adjustments should be made based on patient tolerance. Do not increase, decrease, or discontinue the drug on your own.

Side Effect Management:

Common Reactions: Peripheral edema, fatigue, loss of appetite, and nausea (usually mild to moderate, relieved by symptomatic treatment).

Serious Risks: Interstitial lung disease, hepatotoxicity, and allergic reactions (requires immediate discontinuation of the drug and medical attention).

Drug Interactions and Contraindications:

Interactions: Concomitant use with strong CYP3A4 inhibitors (such as clarithromycin) or inducers (such as rifampicin) may affect drug efficacy. Inform your doctor of any current medications.

Contraindications: Individuals with allergies to the ingredients, severe hepatic or renal impairment, and pregnant or lactating women (contraceptive measures should be used).

Recommended Use: Monitor as directed by your doctor: Regular liver function tests, blood counts, and imaging studies should be performed during treatment to assess efficacy.

Medical Instructions: If symptoms such as difficulty breathing, persistent fever, or jaundice occur, contact your doctor immediately to adjust your regimen. Capmatinib is a prescription drug, and patients must strictly follow their doctor’s instructions to ensure the safety and effectiveness of treatment.